Early Detection Saves Lives

Our purpose is to find and eliminate cancer. Treatments are more successful and survival rates improve with early detection. By combining high sensitivity imaging technologies with nanoparticle technology, we aim to make the detection of diseases like cancer better and safer for patients as well as provide new methods for therapeutic intervention.

Our technology

Founding History

The company was founded as Senior Scientific, LLC by Edward R. Flynn, PhD. Dr. Flynn was formerly employed at the Los Alamos National Laboratory (LANL) and is a recipient of the Alexander von Humboldt Award for Senior American Scientists and is recognized as a Fellow of LANL and the American Physical Society.

The mission of the company was to develop a more sensitive technology to find cancer after Dr. Flynn’s wife developed breast cancer. The technology is based on Dr. Flynn’s expertise in physics of magnetic fields and utilizes a combination of magnetism and nanotechnology to detect cancer earlier when the cancer is still small and can be more effectively treated.

Dr. Flynn pioneered the field of Superparamagnetic Relaxometry (SPMR) and funded the proof-of-principle development of the technology through Small Business Innovative Research grants (SBIR) from the National Institutes of Health and the Department of Defense.

The company was acquired in June of 2011 by Manhattan Scientifics (OTCQB: MHTX) to develop the technology for commercial uses. In November 2016, Senior Scientific was spun out from Manhattan Scientifics as Imagion Biosystems, Inc. Imagion Biosystems, Limited became an ASX listed company (ASX:IBX) in June 2017.

Senior Management

Board of Directors

Scientific Advisory Board